DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
DEBBRAH
Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced
Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis:
Results from Cohort 5 of the DEBBRAH Study
BREAST
SABCS
2023
LUPER
Lurbinectedin In Combination With Pembrolizumab In Relapsed Small Cell Lung Cancer (SCLC): The Phase 1/2 LUPER Study
LUNG
ESMO
2023
ORPHEUS
A phase 2 study of the efficacy and safety of INCMGA00012 in advanced penile squamous cell carcinoma (PSqCC): ORPHEUS
PENILE
ASCO
2023
PHERGAIN (sub-study)
Validation of a genomic assay in early-stage HER2+ breast cancer treated with trastuzumab and pertuzumab (HP): a correlative analysis from PHERGain phase II trial
BREAST
ESMO
2023
ATRACTIB
Efficacy and safety of first-line atezolizumab, bevacizumab, and paclitaxel in
patients with advanced triple-negative breast cancer (aTNBC):
the ATRACTIB phase II trial.
BREAST
SABCS
2023
PARSIFAL
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
BREAST
(Journal) The Oncologist
2023
BIOPER
Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
BREAST
(Journal) Clinical Cancer Research
2023
PARSIFAL
ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following
endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
BREAST
SABCS
2023
DEBBRAH
Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low
Advanced Breast Cancer and Pathologically Confirmed
Leptomeningeal Carcinomatosis: Results from Cohort 5 of the
DEBBRAH Study
BREAST
SABCS
2023
LUPER
en proceso
LUNG
ESMO
2023
PALMIRA
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
BREAST
ASCO
2023
ATRACTIB
Efficacy and safety of first-line atezolizumab + bevacizumab +
paclitaxel in patients with advanced triple-negative breast cancer:
the ATRACTIB phase 2 trial
BREAST
SABCS
2023
Other MEDSIR related articles
